- About Us
- Advertise
- Contact Us
- CureToday.com
- CancerNetwork.com
- OncLive.com
- Do Not Sell My Information
- Privacy
- Terms & Conditions
© 2021 MJH Life Sciences™ , Targeted Oncology - Immunotherapy, Biomarkers, and Cancer Pathways. All rights reserved.
Noa Biran | Authors
Articles
Novel Targets in Relapsed and Relapsed/Refractory Multiple Myeloma
April 13, 2015
Article
Current approaches to the management of multiple myeloma (MM), in particular the introduction of proteasome inhibitors (PIs) and immunomodulatory agents (IMiDs), have improved the survival of patients.